CA2795671A1 - Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto - Google Patents
Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto Download PDFInfo
- Publication number
- CA2795671A1 CA2795671A1 CA2795671A CA2795671A CA2795671A1 CA 2795671 A1 CA2795671 A1 CA 2795671A1 CA 2795671 A CA2795671 A CA 2795671A CA 2795671 A CA2795671 A CA 2795671A CA 2795671 A1 CA2795671 A1 CA 2795671A1
- Authority
- CA
- Canada
- Prior art keywords
- skin
- treatment
- tissue volume
- gene
- radio frequency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract 39
- 238000011282 treatment Methods 0.000 title claims abstract 34
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 32
- 230000002068 genetic effect Effects 0.000 title claims 3
- 230000014509 gene expression Effects 0.000 claims abstract 14
- 230000002500 effect on skin Effects 0.000 claims abstract 7
- 230000003827 upregulation Effects 0.000 claims abstract 5
- 102000008186 Collagen Human genes 0.000 claims abstract 4
- 108010035532 Collagen Proteins 0.000 claims abstract 4
- 108090000695 Cytokines Proteins 0.000 claims abstract 4
- 102000004127 Cytokines Human genes 0.000 claims abstract 4
- 229920001436 collagen Polymers 0.000 claims abstract 4
- 230000002757 inflammatory effect Effects 0.000 claims abstract 4
- 238000007634 remodeling Methods 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 3
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- 230000001105 regulatory effect Effects 0.000 claims abstract 2
- 230000001815 facial effect Effects 0.000 claims 11
- 238000011269 treatment regimen Methods 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 238000011418 maintenance treatment Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000005670 electromagnetic radiation Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
A gene panel comprising genes regulated in mammalian skin in response to generation of a radio frequency current in a tissue volume of the mammalian skin sufficient to heat the tissue volume to a treatment temperature, wherein at least one gene is selected from Table 1 or Table 2 and at least one gene is selected from Table 3. Further there is a method for providing a benefit to mammalian skin, the benefit comprising inducing collagen formation and/or dermal remodeling in a dermal layer of the mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the method comprising generating a radio frequency current in a tissue volume of the mammalian skin for a treatment cycle sufficient to heat the tissue volume to a treatment temperature while avoiding an upregulation in expression of genes listed in Table 3.
Claims (36)
1. A gene panel comprising genes regulated in mammalian skin in response to generation of a radio frequency current in a tissue volume of the mammalian skin sufficient to heat the tissue volume to a treatment temperature, wherein at least one gene is selected from Table 1 or Table 2 and at least one gene is selected from Table 3.
2. A gene panel according to claim 1, wherein at least one gene is selected from Table 1, at least one gene is selected from Table 2, and at least one gene is selected from Table 3.
3. A microarray comprising a set of immobilized nucleic acid probes capable of hybridizing to and detecting genes constituting a gene panel according to claims 1 or 2.
4. A method for providing a benefit to mammalian skin, the benefit comprising inducing collagen formation and/or dermal remodeling in a dermal layer of the mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the method comprising generating a radio frequency current in a tissue volume of the mammalian skin for a treatment cycle sufficient to heat the tissue volume to a treatment temperature while avoiding an upregulation in expression of genes listed in Table 3.
5. The method according to claim 4, wherein the generating step is performed a plurality of times in one treatment cycle.
6. The method according to claim 5, wherein one or more treatment cycles are conducted across a treatment period.
7. The method according to claim 4, wherein a treatment cycle lasts about one minute.
8. The method according to claim 7, wherein a treatment cycle lasts between about 2 and about 6 minutes.
9. The method according to claim 6 wherein the treatment period is at least one week and comprises at least one treatment cycle.
10. The method according to claim 9, wherein the treatment period is between one week and 12 weeks.
11. The method according to claim 10, wherein the treatment period is between 3 and 8 weeks.
12. The method according to claim 11, wherein each week of the treatment period comprises between one and six treatment cycles.
13. The method according to claim 4 wherein the treatment temperature effectuates a skin surface temperature over the tissue volume of less than about 45°C.
14. The method according to claim 4 wherein the treatment temperature effectuates a skin surface temperature over the tissue volume of between about 37°C and about 43°C.
15. The method according to claim 4 further comprising: assessing the benefit by extracting mRNA
from a sample obtained from the tissue volume; and determining an expression profile of a gene panel consisting of at least one gene selected from Table 1 and/or Table 2 and at least one gene selected from Table 3, wherein an expression profile reflecting upregulation of genes selected from Tables 1 and/or 2 combined with substantially no change in expression of genes selected from Table 3 is indicative of a benefit being provided.
from a sample obtained from the tissue volume; and determining an expression profile of a gene panel consisting of at least one gene selected from Table 1 and/or Table 2 and at least one gene selected from Table 3, wherein an expression profile reflecting upregulation of genes selected from Tables 1 and/or 2 combined with substantially no change in expression of genes selected from Table 3 is indicative of a benefit being provided.
16. The method according to claim 15 further comprising optimizing the benefit by adjusting the treatment temperature in response to the expression profile wherein upregulation of the genes selected from Table 1 and/or Table 2 is maximized while expression of genes selected from Table 3 is maintained at substantially no change.
17. The method according to claim 5, wherein the benefit is maintained beyond the treatment period by one or more maintenance treatments, each maintenance treatment comprising at least one maintenance cycle.
18. A method for assessing treatment efficacy of an energy delivery device designed to provide a benefit to skin by heating the skin, the method comprising: treating the skin by application of the energy delivery device; extracting mRNA from a sample of the treated skin; and generating an expression profile for a gene panel according to claims 1 or 2.
19. A method of screening a facial skin treatment regimen for efficacy in providing a collagen and/or dermal remodeling benefit to mammalian skin without stimulating a skin-damaging inflammatory cytokine response, the method comprising: treating facial skin according to a treatment regimen;
extracting mRNA from a sample of the treated facial skin; generating a gene expression profile for a gene panel according to claims 1 or 2; comparing the gene expression profile to a reference profile; and determining that the facial treatment regimen is efficacious where the expression profile reflects upregulation of genes selected from Table 1 and/or Table 2 and a substantial lack of regulation of genes selected from Table 3.
extracting mRNA from a sample of the treated facial skin; generating a gene expression profile for a gene panel according to claims 1 or 2; comparing the gene expression profile to a reference profile; and determining that the facial treatment regimen is efficacious where the expression profile reflects upregulation of genes selected from Table 1 and/or Table 2 and a substantial lack of regulation of genes selected from Table 3.
20. The method according to claim 19, wherein the facial skin treatment regimen comprises generating a pulsed radio frequency current through a first tissue volume of the facial skin over a treatment cycle with a radio frequency current generating device.
21. The method according to claim 20, wherein the treatment regimen further comprises moving the radio frequency current generating device and generating a pulsed radio frequency current through a second tissue volume of the facial skin during the treatment cycle.
22. The method according to claim 19, wherein the facial skin comprises periauricular skin and the sample is obtained by biopsy of treated periauricular skin and the reference is obtained by biopsy of pre-treated or non-treated periauricular skin.
23. The method according to claim 22 wherein the pre-treated or non-treated periauricular reference skin comprises skin substantially adjacent to the treated periauricular skin.
24. The method according to claim 19, wherein genes selected from Table 1 demonstrate a statistically greater than one fold increase in expression over the reference.
25. The method according to claims 19 or 24, wherein genes selected from Table 2 demonstrate a statistically greater than one fold increase in expression over the reference.
26. The method according to claim 20, wherein the facial treatment regimen further comprises application of a cosmetic composition to the facial skin in conjunction with generating the pulsed radio frequency current.
27. The method of screening according to claim 26, wherein the method screens for compositions having an enhancing or potentiating effect on the gene expression profile.
28. The method according to claim 21, wherein the treatment regimen includes a plurality of treatment cycles across a treatment period and wherein a cycle comprises generating a pulsed radio frequency current through a tissue volume of the facial skin for a treatment time sufficient to heat the tissue volume to a treatment temperature.
29. The method according to claim 28 wherein a treatment cycle lasts for more than about 1 minute and effectuates a skin surface temperature over the tissue volume of less than about 45°C.
30. The method according to claim 28 wherein a treatment cycle lasts for between about 1 and 8 minutes and effectuates a skin surface temperature over the tissue volume of between about 37°C
and 43°C.
and 43°C.
31. The method according to claim 28, wherein a treatment cycle lasts for between about 2 and 6 minutes.
32. The method according to claim 28, wherein between two and six treatment cycles are repeated during a week for at least one week.
33. The method according to claim 28, wherein between two and six treatment cycles are repeated during a week for between 3 and 8 weeks.
34. The method according to claim 20, wherein the device comprises at least two bi-polar electrodes which drive the current through the tissue volume when the electrodes are placed across a skin surface comprising the tissue volume and voltage is applied to the electrodes.
35. The methods according to claims 4 or 20 wherein the radio frequency current is driven through the tissue volume in the absence of electromagnetic radiation in the visible light or infrared frequencies of the electromagnetic spectrum and in the absence of supplemental monochromatic or polychromatic light sources directed toward the tissue volume.
36. A genetic signature of differentially expressed genes suitable for identifying a cosmetic skin benefit, the benefit comprising induction of collagen formation and/or dermal remodeling in a dermal layer of mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the genetic signature comprising at least one gene selected from each of Table 1, Table 2, and Table 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32563310P | 2010-04-19 | 2010-04-19 | |
| US61/325,633 | 2010-04-19 | ||
| PCT/US2011/033033 WO2011133538A1 (en) | 2010-04-19 | 2011-04-19 | Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2795671A1 true CA2795671A1 (en) | 2011-10-27 |
Family
ID=44343224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2795671A Abandoned CA2795671A1 (en) | 2010-04-19 | 2011-04-19 | Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2561092A1 (en) |
| JP (1) | JP2013527756A (en) |
| KR (1) | KR20120137407A (en) |
| CN (1) | CN102869789B (en) |
| BR (1) | BR112012026870A2 (en) |
| CA (1) | CA2795671A1 (en) |
| MX (1) | MX2012012235A (en) |
| WO (1) | WO2011133538A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9671410B2 (en) | 2011-01-16 | 2017-06-06 | The Procter & Gamble Company | Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin |
| WO2012135651A1 (en) | 2011-03-31 | 2012-10-04 | The Procter & Gamble Company | Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis |
| US20130261024A1 (en) * | 2012-03-30 | 2013-10-03 | The Procter & Gamble Company | System for Identifying Connections Between Perturbagens and Genes Associated with a Skin Hyperpigmentation Condition |
| US9920357B2 (en) | 2012-06-06 | 2018-03-20 | The Procter & Gamble Company | Systems and methods for identifying cosmetic agents for hair/scalp care compositions |
| WO2014028569A1 (en) | 2012-08-15 | 2014-02-20 | The Procter & Gamble Company | Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders |
| US10966916B2 (en) | 2014-11-10 | 2021-04-06 | The Procter And Gamble Company | Personal care compositions |
| MX376115B (en) | 2014-11-10 | 2025-03-07 | Procter & Gamble | COMPOSITIONS FOR PERSONAL CARE WITH TWO BENEFICIAL PHASES. |
| CN107106429B (en) | 2014-11-10 | 2021-06-29 | 宝洁公司 | Personal care composition with two benefit phases |
| CN111212625B (en) | 2017-10-20 | 2023-05-23 | 宝洁公司 | Aerosol foam skin cleaner |
| WO2019079405A1 (en) | 2017-10-20 | 2019-04-25 | The Procter & Gamble Company | Aerosol foam skin cleanser |
| CN113015904B (en) | 2018-11-29 | 2024-06-18 | 宝洁公司 | Methods for Screening Personal Care Products |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
| US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5366443A (en) | 1992-01-07 | 1994-11-22 | Thapliyal And Eggers Partners | Method and apparatus for advancing catheters through occluded body lumens |
| DE69322266T2 (en) | 1992-04-03 | 1999-06-02 | Perkin-Elmer Corp., Foster City, Calif. | SAMPLES COMPOSITION AND METHOD |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| US5458596A (en) | 1994-05-06 | 1995-10-17 | Dorsal Orthopedic Corporation | Method and apparatus for controlled contraction of soft tissue |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5755753A (en) | 1995-05-05 | 1998-05-26 | Thermage, Inc. | Method for controlled contraction of collagen tissue |
| US5660836A (en) | 1995-05-05 | 1997-08-26 | Knowlton; Edward W. | Method and apparatus for controlled contraction of collagen tissue |
| US6241753B1 (en) | 1995-05-05 | 2001-06-05 | Thermage, Inc. | Method for scar collagen formation and contraction |
| US6430446B1 (en) | 1995-05-05 | 2002-08-06 | Thermage, Inc. | Apparatus for tissue remodeling |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6228078B1 (en) | 1995-11-22 | 2001-05-08 | Arthrocare Corporation | Methods for electrosurgical dermatological treatment |
| US6350276B1 (en) | 1996-01-05 | 2002-02-26 | Thermage, Inc. | Tissue remodeling apparatus containing cooling fluid |
| AU2253397A (en) | 1996-01-23 | 1997-08-20 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| AU779100B2 (en) | 1999-03-09 | 2005-01-06 | Thermage, Inc. | Apparatus and method for treatment of tissue |
| US20020087155A1 (en) * | 1999-08-30 | 2002-07-04 | Underwood Ronald A. | Systems and methods for intradermal collagen stimulation |
| US6702808B1 (en) | 2000-09-28 | 2004-03-09 | Syneron Medical Ltd. | Device and method for treating skin |
| AU2002222328A1 (en) * | 2000-10-18 | 2002-04-29 | Gian Franco Bernabei | Method and apparatus for plasma skin resurfacing |
| US6889090B2 (en) | 2001-11-20 | 2005-05-03 | Syneron Medical Ltd. | System and method for skin treatment using electrical current |
| US6662054B2 (en) | 2002-03-26 | 2003-12-09 | Syneron Medical Ltd. | Method and system for treating skin |
| CN1723058A (en) | 2002-10-07 | 2006-01-18 | 帕洛玛医疗技术公司 | Apparatus for performing photobiostimulation |
| US7643883B2 (en) * | 2005-01-28 | 2010-01-05 | Syneron Medical Ltd. | Device and method for treating skin |
| SI22738A (en) * | 2008-04-11 | 2009-10-31 | Iskra Medical, D.O.O. | Device for radiofrequency circular deep therapy |
-
2011
- 2011-04-19 JP JP2013506231A patent/JP2013527756A/en active Pending
- 2011-04-19 BR BR112012026870A patent/BR112012026870A2/en not_active IP Right Cessation
- 2011-04-19 KR KR1020127026405A patent/KR20120137407A/en not_active Ceased
- 2011-04-19 EP EP11718568A patent/EP2561092A1/en not_active Withdrawn
- 2011-04-19 WO PCT/US2011/033033 patent/WO2011133538A1/en not_active Ceased
- 2011-04-19 CN CN201180019773.9A patent/CN102869789B/en not_active Expired - Fee Related
- 2011-04-19 MX MX2012012235A patent/MX2012012235A/en not_active Application Discontinuation
- 2011-04-19 CA CA2795671A patent/CA2795671A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120137407A (en) | 2012-12-20 |
| JP2013527756A (en) | 2013-07-04 |
| BR112012026870A2 (en) | 2017-01-10 |
| EP2561092A1 (en) | 2013-02-27 |
| CN102869789A (en) | 2013-01-09 |
| MX2012012235A (en) | 2012-11-23 |
| CN102869789B (en) | 2015-09-30 |
| WO2011133538A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2795671A1 (en) | Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto | |
| US20040073079A1 (en) | Method and apparatus for treatment of cutaneous and subcutaneous conditions | |
| US20090054953A1 (en) | Phototherapeutic Method and Apparatus | |
| US20090317911A1 (en) | System and method for photodynamic cell therapy | |
| WO2013096584A3 (en) | Electromanipulation of cells and other biologicaltissues by pulsed electric fields at elevated temperatures | |
| Ji et al. | Comparison of 5-aminolevulinic acid photodynamic therapy and red light for treatment of photoaging | |
| WO2007115220A3 (en) | Hand-held electrical stimulation device | |
| Huo et al. | Noninvasive electromagnetic fields on keratinocyte growth and migration | |
| Liang et al. | Anti-tumor effects of nanosecond pulsed electric fields in a murine model of pancreatic cancer | |
| JP2018522657A (en) | Promoting hair growth | |
| ATE490803T1 (en) | DEVICE FOR TREATING LONG INTERATRIAL DELAYS | |
| Fawzi et al. | Fractional carbon dioxide laser is effective in amelioration of pruritus in primary cutaneous amyloidosis: a clinical and biochemical study | |
| MX2010008765A (en) | Regulation of fibroblastic growth factor-2 (fgf-2) gene expression in living cells with the application of specific and selective electric an electromagnetic fields. | |
| CN106975158A (en) | A kind of beauty instrument and the method that beautifying skin is carried out using the beauty instrument | |
| WO2009106969A1 (en) | Apparatus for carrying out aesthetic treatments, in particular for the treatment of skin stretch marks | |
| Levenberg et al. | Treatment of wrinkles and acne scars using the TriFractional, a novel fractional radiofrequency technology—clinical and histological results | |
| JP2013524946A (en) | Combination of energy and topical composition for regulating mammalian skin condition | |
| JP2010075639A (en) | Method and apparatus for improving skin condition of face and neck | |
| Konstantinović et al. | Effects of near-infrared low-level laser stimulation on neuronal excitability | |
| Lee et al. | Exosomes in Trichology: a literature review | |
| US20230414963A1 (en) | Multi-modal skin treatment device | |
| Yu et al. | Chemogenetic modulation in stroke recovery: A promising stroke therapy Approach | |
| He et al. | Hallmarks of the Aging Skin Microenvironment: Components and Mechanisms | |
| Hossein-Khannazer et al. | Introducing Aurora Kinase A as a Gene Target Against Photoaging: A Network Analysis: Aurora kinase A as a gene target against photoaging | |
| Graeb et al. | P01. 059 Technical features of a medical device generating alternating electric fields (Tumor Treating Fields) for the treatment of glioblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150609 |